PA5-21297

antibody from Invitrogen Antibodies

Targeting: GAD2 GAD65

Western blot (Data presented on provider website)

Immunocytochemistry (Supportive data in Antibodypedia)

Immunohistochemistry (Data presented on provider website)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

PA5-21297

Provider

Invitrogen Antibodies

Product name

GAD65 Polyclonal Antibody

Antibody type

Polyclonal

Antigen

Synthetic peptide

Description

Recommended positive controls: Mouse brain, rat brain. Predicted reactivity: Mouse (100%), Rhesus Monkey (100%). Store product as a concentrated solution. Centrifuge briefly prior to opening the vial.

Reactivity

Human, Mouse, Rat

Host

Rabbit

Isotype

IgG

Vial size

100 µL

Concentration

1 mg/mL

Storage

Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.

References

Submitted references

Effects of electroacupuncture on pain sensation in a rat model of hyperalgesia with nicotine dependence.

Wang SJ, Zhang YP, Candiotti KA
Neural regeneration research 2022 Apr;17(4):905-910

---

Region-Dependent Modulation of Neural Plasticity in Limbic Structures Early after Traumatic Brain Injury.

Hoffman AN, Watson S, Fanselow MS, Hovda DA, Giza C
Neurotrauma reports 2021;2(1):200-213

---

Multiple microRNAs within the 14q32 cluster target the mRNAs of major type 1 diabetes autoantigens IA-2, IA-2β, and GAD65.

Abuhatzira L, Xu H, Tahhan G, Boulougoura A, Schäffer AA, Notkins AL
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2015 Oct;29(10):4374-83

---

Region-specific effects of repeated ketamine administration on the presynaptic GABAergic neurochemistry in rat brain.

Boczek T, Lisek M, Ferenc B, Wiktorska M, Ivchevska I, Zylinska L
Neurochemistry international 2015 Dec;91:13-25

Immunocytochemistry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Immunocytochemistry-Immunofluorescence analysis of GAD65 was performed in Cultured Rat E18 primary cortical neuron, DIV 8. Cells fixed in 4% paraformaldehyde at RT for 15 min. Red: GAD65 Polyclonal Antibody (Product # PA5-21297) diluted at 1:250. Blue: Fluoroshield with DAPI.

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

FIG. 4. Alterations in gamma-aminobutyric acid (GABA) synthesis-related proteins early after lateral fluid percussion injury (FPI). In the ipsilateral basolateral amygdala (BLA), GAD67 was increased at 24 h and decreased in the contralateral BLA at 48 h after FPI (E) . Both GAD65 and GAD67 were significantly increased in the ipsilateral dorsal hippocampus (DH) 6 h after injury (B,F) . GAD67 was also increased in the ipsilateral ventral hippocampus (VH) 6 h after FPI, where GAD65 decreased from 6 h to 24 h following FPI. (G) . In the medial prefrontal cortex (PFC), GAD67 was increased bilaterally at 24 h following injury, and significantly decreased from 48 h to 7 days in contralateral PFC. (H) . Data are represented as mean +- SEM (standard error of the mean); *** p < 0.001, ** p < 0.01, * p < 0.05, relative to sham; # p < 0.05, ## p < 0.01 across injury time-points within each blot.

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Figure 4 Electroacupuncture effects on MOR, beta-EP, GAD67, and GAD65 protein expression in the spinal cord of nicotine-induced hyperalgesic rats . (A-D) Western blot analysis of MOR (A), beta-EP (B), GAD67 (C), and GAD65 (D) in the spinal cord of rats in the three groups. Data (mean +- SEM) are presented as relative values to control levels (CTR: n = 6, NIC: n = 6, NIC + EA: n = 6). * P < 0.05, ** P < 0.01, vs . CTR group; # P < 0.05, ## P < 0.01, ### P < 0.001, vs . NIC group (one-way analysis of variance followed by Newman-Keuls multiple comparison test). CTR: Age-matched control group; NIC: nicotine-exposed group; NIC + EA: nicotine-exposed/electroacupuncture-treated group. GAD65: glutamic acid decarboxylase 65; GAD67: glutamic acid decarboxylase 67; MOR: mu-opioid receptor; beta-EP: beta-endorphin.

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Figure 5 Electroacupuncture effects on MOR, beta-EP, GAD67, and GAD65 protein expression in the PAG of nicotine-induced hyperalgesic rats . (A-D) Western blot analysis of MOR (A), beta-EP (B), GAD67 (C), and GAD65 (D) in the PAG of rats in the three groups. Data (mean +- SEM) are presented as relative values to control levels (CTR: n = 6, NIC: n = 6, NIC + EA: n = 6). * P < 0.05, ** P < 0.01, vs . CTR group; # P < 0.05, ## P < 0.01, vs . NIC group (one-way analysis of variance followed by Newman-Keuls multiple comparison test). CTR: Age-matched control group; NIC: nicotine-exposed group; NIC + EA: nicotine-exposed/electroacupuncture-treated group. GAD65: glutamic acid decarboxylase 65; GAD67: glutamic acid decarboxylase 67; MOR: mu-opioid receptor; PAG: periaqueductal gray; beta-EP: beta-endorphin.